TY -的T1 Eslicarbazepine醋酸与减少发作严重程度除了减少发作频率(P2.031) JF -神经学乔-神经学六世- 86 - 16补充SP - P2.031 AU -乔伊斯·克莱默盟-富尔顿维盟凯瑟琳Anastassopoulos AU - t·克里斯首页托弗·邦德盟Xuezhe王盟-大卫·布卢姆盟-琼娜Moreira AU -弗朗西斯科罗查Y1 - 2016/04/05 UR - //www.ez-admanager.com/content/86/16_Supplement/P2.031.abstract N2 -目的:检查的效果辅助Eslicarbazepine醋酸(ESL)发作严重程度和bothersomeness。背景:在第三阶段,随机、双盲试验(093 - 304),难治性部分性癫痫发作的患者,接受兼职ESL(800毫克或1200 mg QD),明显比接受安慰剂的患者更大的发作频率减少。发作严重程度调查问卷(SSQ),设计用于多维patient-reported评估在临床研究中,在基线管理,14周(两周滴定,12周的维护)三个治疗武器。方法:SSQ总分(TS)和域分数(征兆之前发作的频率和乐于助人[b],严重程度和发作的运动bothersomeness在癫痫(DS)和改变意识,认知、情感、和物理方面的postictal复苏后癫痫[是],和总体严重程度和bothersomeness[…])按方案计算的人口(n = 547)。协方差分析模型、调整基线SSQ分数,估计最小二乘方法(lsm)为每个手臂在14周。LSM差异三个武器相比,建立最小临床意义差异(MCIDs)。结果:总体而言,441年(81.1 [percnt])患者有效SSQ TS在基线和周14。Week 14 LSM TS was significantly lower for ESL 1,200 mg than placebo (2.68 vs 3.20, p<0.001), with the LSM difference (0.52) exceeding the MCID of 0.48. LSMs were also significantly lower for ESL 1,200 mg for DS (3.05 vs. 3.46, p=0.027), AS (1.95 vs. 2.51, p=0.019), and SB (3.09 vs. 3.65, p<0.001) with differences in AS and SB exceeding the MCIDs of 0.39 and 0.48, respectively. For ESL 800 mg subjects, TS, DS, AS, and SB were lower than placebo; however, only SB was significant (3.28 vs. 3.65, p=0.013). CONCLUSIONS: In this post hoc analysis, ESL-treated patients had significantly less seizure severity and bothersomeness than placebo patients. Disclosure: Dr. Cramer has received personal compensation for activities with Bial, Eisai Inc., Sepracor, UCB Pharma, and Sunovion as a consultant. Dr. Velez has received personal compensation for activities with Sunovion as an employee. Dr. Anastassopoulos has received personal compensation for activities with Covance as an employee. Dr. Bond has nothing to disclose. Dr. Wang has received personal compensation for activities with Covance as an employee. Dr. Blum has received personal compensation for activities with Sunovion Pharmaceuticals Inc. as an employee. Dr. Moreira has received personal compensation for activities with BIAL. Dr. Rocha has received personal compensation for activities with Bial as an employee.Sunday, April 17 2016, 8:30 am-5:30 pm ER -